Real-world use of the Breathing Pattern Assessment Tool in assessment of breathlessness post-COVID-19.

Autor: Hylton H; Barts Health NHS Trust, London, UK., Long A; Barts Health NHS Trust, London, UK., Francis C; Barts Health NHS Trust, London, UK., Taylor RR; Barts Health NHS Trust, London, UK., Ricketts WM; Barts Health NHS Trust, London, UK and Barts and The London School of Medicine and Dentistry, London, UK., Singh R; Barts Health NHS Trust, London, UK., Pfeffer PE; Barts Health NHS Trust, London, UK and honorary senior lecturer, Barts and The London School of Medicine and Dentistry, London, UK.
Jazyk: angličtina
Zdroj: Clinical medicine (London, England) [Clin Med (Lond)] 2022 Jul 26; Vol. 22 (4), pp. 376-379. Date of Electronic Publication: 2022 Jul 26.
DOI: 10.7861/clinmed.2021-0759
Abstrakt: Introduction: Breathing pattern disorders (BPDs) are a common cause of chronic breathlessness, including after acute respiratory illnesses such as COVID pneumonia. BPD is however underdiagnosed, partly as a result of difficulty in clinically assessing breathing pattern. The Breathing Pattern Assessment Tool (BPAT) has been validated for use in diagnosing BPD in patients with asthma but to date has not been validated in other diseases.
Methods: Patients undergoing face-to-face review in a post-COVID clinic were assessed by a respiratory physician and specialist respiratory physiotherapist. Assessment included a Dyspnoea-12 (D12) questionnaire to assess breathlessness, physiotherapist assessment of breathing pattern including manual assessment of respiratory motion, and BPAT assessment. The sensitivity and specificity of BPAT for diagnosis of BPD in post-COVID patients was assessed.
Results: BPAT had a sensitivity of 89.5% and specificity of 78.3% for diagnosing BPD in post-COVID breathlessness. Patients with a BPAT score above the diagnostic cut-off had higher levels of breathlessness than those with lower BPAT scores (D12 score mean average 19.4 vs 13.2).
Conclusion: BPAT has high sensitivity and moderate specificity for BPD in patients with long COVID. This would support its use as a screening test in clinic, and as a diagnostic tool for large cohort studies.
(© Royal College of Physicians 2022. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: